Lowest Price Guaranteed
Pages
191
Last Updated
April 2026
View Count
15021
The global continuous bioprocessing market is valued at USD 477.8 million in 2025 and is estimated to be worth USD 886.1 million in 2035, growing at a CAGR of 6.4% during the forecast period.
 |
To learn more about this report, request a free sample copy
Given the growing incidences of chronic diseases across the globe, pharmaceutical companies are experiencing the burden of developing biopharmaceutical drugs to treat patients. Over the years, drug developers have been using conventional batch and fed-batch process for biomanufacturing. These traditional batch processing technologies have several shortcomings, such as slow production, limited efficiency, risk of human errors, and contamination during material transfer.
Moreover, traditional bioreactors require plenty of time for cleaning, which is equal to the time required for bioprocessing. With the rising demand for modern biopharmaceuticals, it can be difficult to maintain consistency in biopharmaceutical drug manufacturing and commercialization. In order to overcome these concerns, continuous bioprocessing emerges as a better alternative to manufacture biopharmaceuticals faster and more efficiently.
 |
 |
 |
Continuous bioprocessing refers to the single-unit processing system with biomanufacturing in which raw material is continuously loaded, processed, and harvested. The primary objective behind integrating continuous bioprocessing is to increase biopharmaceutical production and output to meet the growing requirement for drugs.
Furthermore, continuous bioprocessing technology is characterized by short downtime, end-to-end bioprocess, and faster operation with no or less sterilization. It is interesting to note here that continuous bioprocessing systems have significantly addressed challenges associated with conventional bioprocessing systems, such as low production and inefficiency. Additionally, the usage of continuous bioprocessing reduces manufacturing cost (by 60%), optimization of resins (by 70%) in chromatography columns, reduces buffer use (by 30-50%), reduces product change over time (by 90%), minimize facility footprints (by 50-70%), improved product consistency across different processing batches (by 50%) and reduction in operation cost (by 90%).
Driven by the significance offered, several pharmaceutical companies have taken a shift to continuous bioprocessing. Currently, users of this novel technology are focusing on upgrading individual bioprocessing operations to continuous processes to leverage operational flexibility, speed, and quality. Although continuous bioprocessing has been adopted as a future technology to streamline biopharmaceutical production, there are several challenges that need to be addressed, such as alignment with existing manufacturing equipment and complexity associated with upstream processing.
It is worth noting here that the key players in this industry are accelerating their efforts to integrate next-generation sensors for real-time analysis in the upstream and downstream processes. For instance, in August 2023, Sartorius and Repligen entered into a collaboration and successfully launched an Integrated Bioreactor system that features RepligenXCell ATF upstream intensification technology within the Sartorius Biostat STR bioreactor. This technology has simplified the N perfusion and seed train for biopharmaceutical manufacturers, making it less time consuming and ensures easy scalability.
Owing to the growing technological advances and rising adoption by pharmaceutical companies, we believe that the technology developers will continue to make investments in this field, which is anticipated to drive the market at a steady pace during the forecast period.
The market report study covers an in-depth analysis of various industrial leaders who are currently engaged in this industry across various segments, as mentioned in the table below.
| Key Report Attributes | Details | |
| Historical Trend | Since 2019 | |
| Forecast Period | Till 2035 | |
| Market Size 2035 | USD 886.1 million | |
| CAGR | ~6.4% | |
| Distribution by Type of Manufacturer |
|
|
| Distribution by Company Size |
|
|
| Type of Scale of Operation |
|
|
| Stage of Bioprocess |
|
|
| Key Geographical Regions |
|
|
| Key Companies Profiled |
|
|
| PowerPoint Presentation (Complimentary) |
Available | |
| Customization Scope | 15% Free Customization | |
| Excel Data Packs (Complimentary) |
|
|
 |
 |
 |
One of the key objectives of the report was to estimate the current market size and the growth opportunities in the continuous and semi-continuous bioprocessing market over the next decade. Based on different parameters, such as global biopharmaceutical market, cost of goods sold, manufacturing cost of biologics, share of API manufacturing, upstream and downstream costs in biologics manufacturing, we have provided informed estimates on the evolution of the market for the forecast period till 2035.
In order to provide a detailed future outlook, year-wise projections of the current and forecasted opportunity have been further segmented across [A] type of manufacturer (innovator / drug developer and contract service provider), [B] company size (large, mid-sized and small), [C], scale of operation (preclinical / clinical and commercial), [D] stage of bioprocess (upstream and downstream), and [E] key geographical regions (North America, Europe, Asia-Pacific and Rest of the World). In order to account for the uncertainties and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base, and optimistic tracks of the market's evolution.
The opinions and insights presented in the report are backed by a deep understanding of key insights generated from both secondary and primary research. The perceptions presented in this study were also influenced by discussions held with senior stakeholders in this industry. The report features detailed transcripts of interviews held with the following individuals:
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD unless otherwise specified.
Based on the type of manufacturers, the continuous bioprocessing market is segmented into innovator / drug developer and contract service provider. According to our projection, contract service providers accounts to hold the largest share (56%) of the overall market. The highest growth share is likely due to the higher adoption rate of continuous bioprocessing technology by the CMOs and growing outsourcing of biologics manufacturing to reduce the cost of drug development and enhancement of productivity. CDMOs are investing in technology platform development and facility expansions to allow continuous manufacturing of biologics. In January 2024, India based CDMO, Enzene Biosciences, opened its first facility in the US which will host multiple continuous manufacturing lines based on their proprietary technology platform EnzeneXTM.
It is worth noting that the trend of growth is likely to remain unchanged, and contract service providers will grow at a CAGR of 7% during the forecast period till 2030.
The global continuous bioprocessing market is bifurcated into large, mid-sized, and small companies. Based on our market analysis, large-sized companies account for the largest share (66%) of the market. The highest growth share can be predicted by the continuous investment in advanced technologies by large companies for efficient bioprocessing. Furthermore, large companies also provide well-established infrastructure to support the complex continuous bioprocessing operations. It is worth highlighting here that the trend of growth is likely to remain unchanged and large companies will grow at a CAGR of 7% during the forecast period.
Based on the scale of operation, the global market is segmented into preclinical / clinical and commercial operations. According to our projection, commercial operation holds the largest (53%) of continuous bioprocessing market share. This can be attributed to the fact that continuous bioprocessing has been used to manufacture biopharmaceuticals on a large scale for commercialization. It is worth highlighting here that owing to the growing usage of continuous bioprocessing technology for commercial purposes, this segment is likely to grow at a higher CAGR during the forecast period.
Depending on the stage of bioprocessing, the continuous bioprocessing market is bifurcated into upstream and downstream processes. According to our projection, currently, upstream bioprocessing occupies the highest share (88%) of the market. The highest growth share is likely to be the result of the high demand for perfusion culture techniques for the constant feeding of fresh media into the continuous bioreactor.
It helps to maintain cell viability during the high growth phase, which further leads to higher yield. It is worth noting here that the trend of growth is likely to remain unchanged during the projected period, and this segment will grow at a healthy CAGR during the forecast period Till 2035.
Based on geographical insight, the continuous bioprocessing market is distributed in North America, Europe, Asia-Pacific, and the rest of the world. According to our projection, Europe holds the largest share (41%) of the overall revenue share. This significant growth share can be attributed to the fact that the European region is the headquarters of key industrial leaders who are presently focusing on innovations in continuous bioprocessing technologies.
In addition to innovation, the key players are continuously focusing on the development of cutting-edge bioprocessing technologies that continuously help develop therapeutic drugs with high efficacy and safety profiles. In September 2024, Just-Evotec Biologics announced the opening of a 15,000 square meter J.POD facility in France. Built with an investment of EUR 150 million, the facility contains continuous manufacturing platform for antibody therapeutics and proteins with Fc region.
However, in Asia-Pacific and the rest of the world, the market for semi-continuous and continuous bioprocessing will expand at a higher CAGR during the forecast period, because a number of large biologics contract manufacturing companies are based in the region. A South Korea based CDMO, Lotte Biologics announced its plans to open three domestic manufacturing plants, which will have a combined capacity of 400,000 liters. The first of the three plants will also have N-1 perfusion system for large scale antibody based therapeutic manufacturing.
The “Continuous Bioprocessing Market: Industry Trends and Global Forecasts, till 2035” report features an extensive study on the companies having continuous and semi-continuous bioprocessing capabilities. The study underlines an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain.
Presently, the market landscape features over 70 companies that are engaged in this field to develop innovative, continuous bioprocessing technologies. Overall, the market seems highly fragmented, featuring the presence of both small firms and well-established players who provide continuous bioprocessing services to process a broad range of biologics at different scales.
In order to cater to the continuously evolving requirements of pharmaceutical companies, industrial leaders active in this industry are expanding their perfusion capabilities and converting them into continuous bioprocessing facilities. Some large CDMOs like WuXi Biologics have developed a complete continuous manufacturing platform WuXiUPTM integrating ATF (alternating tangential flow), BioSMB (bio-simulated moving bed), PCC (periodic counter-current chromatography) and Raman spectroscopy.
As biopharmaceutical manufacturers continue to leverage advanced technologies for upstream and downstream processing, we believe the continuous bioprocessing market witnesses an upward trajectory substantially during the forecast period.
Given the growing demand for biopharmaceutical drugs to target a wide range of disease indications, pharmaceutical companies are adopting continuous bioprocessing systems over conventional batch processing methods. It is worth highlighting here that semi-continuous and continuous bioprocessing approaches offer higher operational efficiency, reduce production costs, and enable controlled production. The advantage offered by continuous bioprocessing technology has become a primary reason behind its adoption. Although, currently a hybrid or semi-continuous bioprocessing is more common.
The manufacturers are also developing continuous manufacturing platforms for growing types of biologics. As mRNA based therapeutics gained attention during the COVID-19 pandemic, Recipharm received FDA grant of USD 82 million for development of continuous mRNA manufacturing platform. Additionally, a number of biosimilar manufacturers are also evaluating continuous / semi-continuous platforms driven by the benefits in cost of goods manufactured. As stated by Himanshu Gadgil, CEO of Enzene “Lower operational costs and higher productivity can enable up to 50% reductions in overall production cost per gram.” In April 2024, Alvotech announced FDA approval for its Stelara biosimilar, Selarsdi. As per the company, the biosimilar is manufactured using a continuous perfusion process.
Despite the significance offered by the technology for large-scale production of biologics, several challenges may hinder market growth in the coming years. One of these challenges involves high upfront costs for the installation of continuous bioprocessing technology and a lack of skilled personnel for systematic operations. Furthermore, technological complexity, such as high-tech design and scalability issues, can create difficulties in the adoption of these technologies, specifically by small companies. In addition to the aforementioned challenges, complex regulatory guidelines for continuous bioprocessing may require extensive documentation and validation processes, which create significant challenges for industrial leaders.
In order to streamline manufacturing for biologics, several technology developers are looking forward to integrating AI and data analytics in continuous bioprocessing systems to optimize process efficiency. The growing innovation within continuous bioprocessing systems and the integration of AI technology offer lucrative opportunities to improve operational efficiency.
Furthermore, various industrial leaders are also focusing on sustainability to reduce wastage and energy consumption, which is anticipated to be a major growth factor of the continuous bioprocessing market. It is worth highlighting here that the growing integration of single use bioprocessing technologies in continuous bioprocessing workflows to reduce the risk of contamination and enhance scalability is also a key factor of market growth during the forecast period.
Examples of key companies engaged in semi-continuous and continuous bioprocessing industry (which have also been profiled in this market report; the complete list of companies is available in the full report) include AGC Biologics, Biogen, Bristol-Myers Squibb, Sanofi Genzyme, FUJIFILM Diosynth Biotechnologies, Merck KGaA, Novasep, UCB Pharma, Enzene Biosciences and WuXi Biologics.
This market report includes an easily searchable excel database of all the companies using semi-continuous and continuous bioprocessing for manufacturing, worldwide.
Amongst other elements, the report includes:
 |
 |
 |
Several recent developments have taken place in the field of continuous and semi-continuous bioprocessing industry. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.